Edesa Biotech, Inc. EDSA
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Edesa Biotech, Inc. (EDSA) is a healthcare company listed in the US with a market value of about $26M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -145%.
About Edesa Biotech
Edesa Biotech is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $758689 in 2015 to $780000 in 2022, growth of about 0.4% a year. It was profitable in 0 of the last 10 years in our data.
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $780000 | $10M | $328801 | $0 | $228287 | $1M | $758689 |
| Net income | -$7M | -$6M | -$8M | -$18M | -$13M | -$6M | -$2M | -$5M | -$5M | -$3M |
| Free cash flow | — | — | -$7M | -$12M | -$14M | -$5M | -$1M | -$5M | -$5M | -$5M |
| EPS (diluted) | $-1.27 | $-1.93 | $-2.93 | — | $-1.10 | $-0.74 | $-0.47 | $-3.44 | $-3.99 | $-2.52 |
| Net margin | — | — | — | -2249.9% | -129.0% | -1935.3% | — | -2203.7% | -395.2% | -374.7% |
| ROIC | -50.2% | -276.9% | -102.0% | -154.2% | -142.2% | -74.4% | -39.8% | -55.8% | -31.5% | -42.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Edesa Biotech pay a dividend?
Not currently.
Is Edesa Biotech a good stock to buy?
We do not give buy or sell advice. Edesa Biotech scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.